First trimester screening for pre-eclampsia

Obstetric Medicine - Tập 9 Số 3 - Trang 106-112 - 2016
Stefan C. Kane1,2
1Department of Obstetrics and Gynaecology, The University of Melbourne, Melbourne, Australia
2Pregnancy Research Centre, Department of Maternal-Fetal Medicine, The Royal Women’s Hospital, Parkville, Victoria Australia

Tóm tắt

The commercial availability of tests in the first trimester of pregnancy that predict the later development of pre-eclampsia has prompted considerable debate regarding their clinical utility and the degree to which they fulfil the longstanding principles of screening. Such tests have been shown to achieve detection rates for early pre-eclampsia (requiring delivery prior to 34 weeks) of over 90%, for a false positive rate of 10%. However, their capacity to predict later onset pre-eclampsia, which accounts for the bulk of the disease burden, is much more limited. The relatively few studies validating the performance of these tests in different populations have demonstrated significant variations in performance. Moreover, prospective research confirming that the administration of aspirin to those screened to be high risk reduces the incidence of pre-eclampsia is yet to be completed, and there may be harms in restricting aspirin therapy to this group, given its broader beneficial effect. In light of these limitations, further development of these tests is recommended prior to their introduction to clinical practice.

Từ khóa


Tài liệu tham khảo

Wilson J, 1968, Principles and practice of screening for disease (public health papers)

10.1016/j.placenta.2010.07.015

10.1111/ajo.12151

10.1111/ajo.12126

10.1038/nrendo.2014.199

10.7326/M14-1884

10.1016/j.preghy.2014.01.003

10.1136/bmj.c2207

Task Force on Hypertension in Pregnancy ACOG, 2013, Obstet Gynecol, 122, 1122, 10.1097/01.AOG.0000437382.03963.88

10.3109/07420528.2012.717455

Roberge S, Am J Perinatol

10.1097/AOG.0b013e3181e9322a

10.1002/pd.4403

Duley L, 2007, Cochrane Database Syst Rev, 2, Cd004659

10.1016/S0140-6736(07)60712-0

10.1002/uog.12470

Hofmeyr GJ, 2010, Cochrane Database Syst Rev, 8, Cd001059

10.1136/bmj.38380.674340.E0

10.3109/01443615.2011.635224

10.1038/jhh.2009.45

10.1136/bmj.39540.522049.BE

10.1161/HYPERTENSIONAHA.107.104646

10.1111/j.1471-0528.2006.00882.x

Khong SL, 2015, Dis Mark, 2015, 679730

10.1002/uog.13275

10.1186/s12884-015-0608-y

10.1016/j.placenta.2011.11.021

10.1186/1477-7827-7-70

10.1097/AOG.0b013e3182571669

10.1016/j.ajog.2012.11.003

10.1186/1471-2393-13-226

10.1002/uog.12360

Martin A, 2014, Prenat Diagn, 34, 685, 10.1002/pd.4416

10.1016/j.siny.2013.11.013

10.1161/HYPERTENSIONAHA.108.127977

10.1002/uog.12264

10.1016/j.placenta.2011.05.006

10.1002/uog.6280

10.1016/j.ajog.2012.12.016

10.1002/uog.7439

10.1002/pd.4519

Poon LC, 2010, Ultrasound Obstet Gynaecol, 35, 662, 10.1002/uog.7628

10.1002/pd.2440

10.1002/pd.2660

10.1159/000356171

10.1002/uog.13435

10.1002/uog.14819

10.1097/AOG.0000000000001049

10.1111/ajo.12253

10.1111/1471-0528.13052

10.1016/j.ajog.2013.02.042

10.1161/HYPERTENSIONAHA.114.03578

Xiong X, 2002, Am J Obstet Gynecol, 155, 203

Humphrey MD, Bonello MR, Chugtai A, et al. Maternal deaths in Australia 2008 – 2012. Maternal deaths series number 5. Canberra, ACT, Australia: Australian Institute of Health and Welfare, 2015.

10.1016/j.placenta.2013.12.008

10.1371/journal.pmed.1001274

Khalil A, 2013, Ultrasound Obstet Gynecol, 42, 478, 10.1002/uog.12366

10.1159/000366060

10.3310/hta12060

10.1016/j.ajog.2005.08.032

10.1007/s40273-015-0291-x

10.1159/000324320

10.1111/aogs.12482

10.1016/j.midw.2014.04.006

10.1002/uog.12421

10.1016/S2214-109X(14)70227-X

Dolea C and AbouZahr C. Global burden of hypertensive disorders of pregnancy in the year 2000. GBD 2000 working paper. Geneva: World Health Organization, 2003, www.who.int/evidence/bod (2003, accessed 3 May 2016).

10.1053/j.semperi.2009.02.010

10.1016/j.ajog.2004.10.598

Bartsch E, 2015, PloS One, e0116296, 10.1371/journal.pone.0116296

10.1016/j.ajog.2014.04.027

10.1002/uog.14770